Shire

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website www.shire.com.

Shire RSS Channel

List of articles in category Shire
Title	Published Date
Shire enters into novel research collaboration with Italian-based Telethon's Institute of Genetics and Medicine for Rare Diseases	24 October 2012
Shire receives prestigious EURORDIS Company Award for exemplary work in rare diseases	01 March 2012
Shire's Venvanse® (lisdexamfetamine dimesylate) Marketing Application accepted for review	05 January 2012
Shire Announces European Approval of VPRIV® (velaglucerase alfa)	27 August 2010
Shire Proposes to Expand Specialist Gastrointestinal Portfolio	03 August 2010
Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa	25 November 2009
Shire Collaborates with Santaris Pharma A/S on LNA Drug Platform	27 August 2009
Shire withdraws European Application for DAYTRANA™	16 March 2009
Shire to enter European ADHD market with the acquisition of EQUASYM® IR and XL	21 February 2009